6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.

Autor: García-Sanz R; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Dogliotti I; Unit of Haematology, Department of Biotechnology & Health Sciences, University of Torino, Torino, Italy., Zaccaria GM; Unit of Haematology, Department of Biotechnology & Health Sciences, University of Torino, Torino, Italy., Ocio EM; Haematology Department, University Hospital of Marqués de Valdecilla, Santander, Spain., Rubio A; Haematology Department, Miguel Servet Hospital, Zaragoza, Spain., Murillo I; Haematology Department, Miguel Servet Hospital, Zaragoza, Spain., Escalante F; Haematology Department, Hospital Complex of León, León, Spain., Aguilera C; Haematology Department, Regional Hospital of El Bierzo, León, Spain., García-Mateo A; Haematology Department, General Hospital of Segovia, Segovia, Spain., García de Coca A; Haematology Department, University Clinical Hospital of Valladolid, Valladolid, Spain., Hernández R; Haematology Department, Virgen de la Concha Hospital, Zamora, Spain., Dávila J; Haematology Department, Nuestra Señora de Sonsoles Hospital, Ávila, Spain., Puig N; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., García-Álvarez M; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Chillón MDC; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Alcoceba M; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Medina A; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., González de la Calle V; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Sarasquete ME; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., González M; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Gutiérrez NC; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain., Jiménez C; Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.

Publikováno v: British journal of haematology [Br J Haematol] 2021 Mar; Vol. 192 (5), pp. 843-852. Date of Electronic Publication: 2020 Aug 11.

A safety profile of medications used to treat Waldenström's macroglobulinemia.

Autor: García-Sanz R; a Servicio de Hematología, Hospital Universitario de Salamanca , Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer de Salamanca, CIBERONC , Salamanca , Spain., Jiménez C; a Servicio de Hematología, Hospital Universitario de Salamanca , Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer de Salamanca, CIBERONC , Salamanca , Spain., González De La Calle V; a Servicio de Hematología, Hospital Universitario de Salamanca , Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer de Salamanca, CIBERONC , Salamanca , Spain., Sarasquete ME; a Servicio de Hematología, Hospital Universitario de Salamanca , Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer de Salamanca, CIBERONC , Salamanca , Spain.

Publikováno v: Expert opinion on drug safety [Expert Opin Drug Saf] 2018 Jun; Vol. 17 (6), pp. 609-621. Date of Electronic Publication: 2018 Jun 06.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Primary amyloidosis].

Autor: González de la Calle V; Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España., García-Sanz R; Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España. Electronic address: rgarcias@usal.es., Mateos MV; Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España.

Publikováno v: Medicina clinica [Med Clin (Barc)] 2016 Aug 05; Vol. 147 (3), pp. 121-6. Date of Electronic Publication: 2016 Apr 13.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.